about
Lead discovery for Alzheimer's disease related target protein RbAp48 from traditional Chinese medicine.An Overview of Practical Applications of Protein Disorder Prediction and Drive for Faster, More Accurate Predictions.Susceptible gene of stasis-stagnation constitution from genome-wide association study related to cardiovascular disturbance and possible regulated traditional Chinese medicine.Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer.Potential retinoid x receptor agonists for treating Alzheimer's disease from traditional chinese medicine.In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.Lead Screening for HIV of C-C Chemokine Receptor Type 5 Receptor Inhibited by Traditional Chinese Medicine.Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine.In silico design of BACE1 inhibitor for Alzheimer's disease by traditional Chinese medicine.In Silico Investigation of Cytochrome P450 2C9 in relation to Aging Using Traditional Chinese Medicine.In silico design for adenosine monophosphate-activated protein kinase agonist from traditional chinese medicine for treatment of metabolic syndromes.Ligand-based and structure-based investigation for Alzheimer's disease from traditional chinese medicine.In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease.Computational design of apolipoprotein E4 inhibitors for Alzheimer's disease therapy from traditional Chinese medicine.Lead Screening for Chronic Obstructive Pulmonary Disease of IKK2 Inhibited by Traditional Chinese MedicinePotential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancersLead screening for CXCR4 of the human HIV infection receptor inhibited by traditional Chinese medicineLead screening for HIV-1 integrase (IN) inhibited by traditional Chinese medicine.Investigation of potent lead for acquired immunodeficiency syndrome from traditional Chinese medicineInsight into HIV of IFN-induced myxovirus resistance 2 (MX2) expressed by traditional Chinese medicinePossible inhibitor from traditional Chinese medicine for the β form of calcium-dependent protein kinase type II in the treatment of major depressive disorder.In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.In silico investigation of potential mTOR inhibitors from traditional Chinese medicine for treatment of Leigh syndromeAn investigation of small GTPases in relation to liver tumorigenesis using traditional Chinese medicine.The inhibition of folylpolyglutamate synthetase (folC) in the prevention of drug resistance in Mycobacterium tuberculosis by traditional Chinese medicineDrug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.Treatment of cardiovascular disease by traditional Chinese medicine against pregnane X receptorIn silico investigation of potential TRAF6 inhibitor from traditional Chinese medicine against cancers.In silico investigation of potential pyruvate kinase M2 regulators from traditional Chinese medicine against cancers.Investigation of estrogen receptor (ESR1) for breast cancer from traditional Chinese medicinePotential smoothened inhibitor from traditional Chinese medicine against the disease of diabetes, obesity, and cancerInvestigation of the novel lead of melanocortin 1 receptor for pigmentary disorders.Binding cavities and druggability of intrinsically disordered proteins.Identification of inhibitors of biological interactions involving intrinsically disordered proteins.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc.Pharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional chinese medicine.Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma.Digested disorder, Quarterly intrinsic disorder digest (October-November-December, 2013).In Silico Investigation of Traditional Chinese Medicine for Potential Lead Compounds as SPG7 Inhibitors against Coronary Artery Disease.
P2860
Q30366183-C85471A1-2F7B-4184-91C0-544C2A49F90FQ30377015-59C59819-D050-486C-AD43-C98E1CEC797EQ30657668-79A0BF7F-AA59-40CE-8448-7137DBDF4FBEQ33608964-EEC1664D-F9D4-4922-A8C0-82B03113A273Q33614602-1A2A18C0-9739-4F7C-91B9-D4367239600DQ33614632-08E940C4-B7C9-492B-B9E4-602744390BE8Q33615005-490E12C5-A663-4588-9623-AEB1239FC54FQ33661003-3544E75E-D3A2-48FE-B2E2-4C8056EB50C2Q33666808-6A6D0FEA-49B6-4E3A-AAC4-76A19CA96C93Q33668052-0A5C3655-DA62-4B72-B78C-FB7855EBEDA8Q33668408-9AB09BF4-06CA-4E4E-9FC9-997AE161F729Q33668480-A9F85C41-2AC0-4452-94C1-187358258776Q33678309-8F440640-D85E-48EC-B43D-8D9790C2E4BEQ33747644-8611FA41-0F76-4190-A724-A616E19750FFQ33766033-EE45E89A-F93B-41C9-96F4-BCC3A6359A05Q33790946-FA633F52-3A2B-4C6D-9C5E-AA5A798EC57EQ33791008-E4C85E82-94B4-4423-B4D6-137CB468951BQ33810342-BC6665DD-0CAC-4D19-BF5A-83453B3EE16AQ33821293-82BC51B5-F481-43C7-8942-82C4586F9799Q33862420-CBDCCF78-BBD1-4CFB-B38B-7787020E1265Q33862690-965DC405-8CDC-4FF8-80BB-3FB2BEB100B9Q33876257-CEFDE268-530A-493A-AFDB-DE3FC0D763FDQ33876312-C53100B3-1F34-4E41-82A7-A479FAFD2923Q33876492-3598761C-0D76-4DDB-BECD-5D7E843EFA3CQ33876498-35E00328-D236-4512-BEC2-62216EF9627DQ33876519-18EB14C3-5E60-4869-A04B-EC301F327674Q33876600-142A2296-0F0F-4518-AF30-4365CABED881Q33893880-3D95A5E5-86A2-46DF-99E8-2D94A27B7899Q33895166-08ECCA09-CBE3-44F1-A235-B13D2874845CQ33903600-A71142AC-5820-4C7B-92C7-6AA65E4A43A4Q34022289-8D92187A-7422-4FA2-9D15-1E8466EC5ACFQ35137889-01DF1A35-C9DB-4AD1-9653-22016A48E065Q35571730-998AA522-E1B7-4D90-A299-17481B274ABCQ35585498-A5A819B6-DF16-4E90-AA73-09BBC1D95646Q35687836-24CF36C2-B1F3-4DDA-8171-AE11918D9DB7Q36638977-8678DF11-B8FE-4912-94B8-698098E1F74EQ37556518-8C5F655C-035E-4689-A246-5319AECA35EAQ37557811-09FAAE61-F579-4F42-A609-E64FF0DE9171Q42156830-C2218059-0339-405E-83CC-7286EDD74F37Q46550667-53BA1331-A972-4726-B9ED-E29C72DFD024
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
How to design a drug for the disordered proteins?
@ast
How to design a drug for the disordered proteins?
@en
type
label
How to design a drug for the disordered proteins?
@ast
How to design a drug for the disordered proteins?
@en
prefLabel
How to design a drug for the disordered proteins?
@ast
How to design a drug for the disordered proteins?
@en
P1433
P1476
How to design a drug for the disordered proteins?
@en
P2093
Weng Ieong Tou
P304
P356
10.1016/J.DRUDIS.2013.04.008
P577
2013-04-30T00:00:00Z